Journal of Histochemistry and Cytochemistry, Vol. 46, 577-584, May 1998, Copyright © 1998, The Histochemical Society, Inc.


SYMPOSIUM PAPER

Putative Preneoplastic Changes Identified by Enzyme Histochemical and Immunohistochemical Techniques

Theresa P. Pretlowa and Thomas G. Pretlowa
a Institute of Pathology, Case Western Reserve University Medical Center, Cleveland, Ohio

Correspondence to: Theresa P. Pretlow, Inst. of Pathology, Case Western Reserve Univ., 2085 Adelbert Rd., Cleveland, OH 44106.


  Summary
Top
Summary
Introduction
Materials and Methods
Results and Discussion
Literature Cited

Microscopic evaluation of whole-mount colons stained with methylene blue and/or hexosaminidase has identified putative preneoplastic lesions in the colons of rodents treated with carcinogen and in the grossly normal colons of humans. Enzyme histochemistry with glycol methacrylate sections has permitted the identification of putative premalignant lesions in rodent livers, human and rodent colons, and human prostates. Immunohistochemistry with paraffin-embedded tissues has been used to identify and characterize putative premalignant lesions in human colons and prostates. (J Histochem Cytochem 46:577–583, 1998)

Key Words: , enzyme histochemistry, immunohistochemistry, glycol methacrylate embedding, paraffin embedding, premalignant lesions, cancer, colon, prostate, whole-mount tissue


  Introduction
Top
Summary
Introduction
Materials and Methods
Results and Discussion
Literature Cited

THE MALIGNANT TRANSFORMATION of normal cells to malignant ones is a multistep process that occurs over many months to years in most species. During the long period of time (called latency) between the initial administration of carcinogen and the final development of a macroscopically visible tumor, a large number of changes occur in these cells. Histochemistry provides an invaluable tool with which to identify specific cells involved in this process and many of the phenotypic alterations that are observed both in premalignant cells and in cancer cells. Rodents are widely used (Bannasch and Gossner 1994 , Bannasch and Gossner 1997 ) as models of tumorigenesis to study processes that are similar to those that occur in humans. Although the expression of phenotypic alterations in putative premalignant lesions has been studied most extensively in rodent livers (Peraino et al. 1983 ; Pretlow et al. 1987 ), we shall devote most of our discussion to alterations observed in colons and, more recently, in prostates. Many histochemical techniques have contributed to our understanding of premalignant lesions and cancer. Here we focus on the insights gained about neoplasia through the use of whole-mount tissues, glycol methacrylate-embedded tissues for enzyme histochemistry, and paraffin-embedded tissues for immunohistochemistry.


  Materials and Methods
Top
Summary
Introduction
Materials and Methods
Results and Discussion
Literature Cited

Specimens and Animal Protocols
Grossly normal human colonic mucosa and sections of human prostate were obtained for us by the Western Division of the Cooperative Human Tissue Network of the National Cancer Institute located at Case Western Reserve University. For experimental animal protocols, the reader is referred to the original articles cited for the specific studies.

Identification of Aberrant Crypt Foci (ACF) in Whole-mount Colons
Bird 1987 first identified ACF in whole-mount preparations of colons from carcinogen-treated rodents. The colons are rapidly removed, cleaned in an isotonic solution, such as 0.9% NaCl at 4C, and fixed flat. The type of fixative and the conditions of fixation are dictated by the subsequent techniques that are to be used. For routine microscopic evaluation of ACF in unembedded tissue after staining for 3–5 min with 0.2% methylene blue (Chroma-Gesellschaft Schmid, distributed by Roboz Surgical Instruments, Washington, DC), an extended fixation in formalin (neutral-buffered, 10% w/v, phosphate buffer, pH 7.0) (Fisher Scientific; Pittsburgh, PA) at room temperature (RT) works well. If subsequent enzyme-histochemical evaluation of the ACF is planned, fixation in 2% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4) for 2 hr at 4C (Pretlow et al. 1990 , Pretlow et al. 1993b ) is required to preserve the activity of some enzymes. For immunohistochemistry, initial fixation for 1 hr in formalin or 4% paraformaldehyde at RT works well for most antigens (Pretlow et al. 1994c ). More recently, we have obtained better morphology with formalin fixation for 1 hr at 4C. A more even distribution of stain is obtained if the stained tissue is held for 30 min or more in 1% paraformaldehyde at 4C before it is viewed. The wet, fixed tissue is placed on a glass microscope slide with the mucosal side up and is viewed with a regular microscope or a dissecting microscope at x30–100 magnification [rodent colon has smaller crypts (Figure 1A) and requires higher magnification than is required for the larger crypts found in human mucosa (Figure 1B and Figure 1C)]. ACF are not as easily identified in sections of embedded colons as they are in unembedded colons. To assist in the location of ACF or other specific microscopic lesions after they are embedded, the lesions are painted with permanent ink (Davidson Marking System; Bradley Products, Bloomington, MN) with a fine needle while viewed under the microscope.



View larger version (114K):
[in this window]
[in a new window]
 
Figure 1. Aberrant crypt foci (arrows) in methylene blue-stained whole-mount colon from a carcinogen-treated rat (A) and from grossly normal human colon (B,C). Serial sections of an enzyme-altered focus of two crypts, identified with arrows, from the colon of a carcinogen-treated rat. (D) Decreased expression of hexosaminidase as visualized by a red precipitate in the normal adjacent crypts. (E) Decreased expression of {alpha}-naphthyl butyrate esterase as visualized by a red-brown precipitate. (F) Decreased goblet cells that contain mucin, as visualized with periodic acid–Schiff (PAS) reagent. Whole-mount colon, stained for hexosaminidase, from a carcinogen-treated rat reveals three foci with aberrant morphology and loss of hexosaminidase activity (G) and one focus with normal morphology and loss of hexosaminidase activity (H). Bars: A,B,G = 200 µm; C = 500 µm; DF,H = 80 µm.

Fixed, unembedded tissue can be stained for the demonstration of enzyme activity, such as hexosaminidase, by using the same substrates as used for enzyme histochemistry with histological sections (Pretlow et al. 1993b ). Alternatively, we found that colon tissue can be stained with methylene blue, evaluated, and then stained for demonstration of hexosaminidase to enable direct comparison of the two methods. Others (Caderni et al. 1995 ) have demonstrated sialomucins and sulfomucins in whole-mount colon mucosa stained with high-iron diamine–alcian blue (HID-AB).

Enzyme Histochemistry with Glycol Methacrylate-embedded Tissue
Tissues embedded in glycol methacrylate (JB-4 embedding kit, Polysciences, Warrington, PA; molds and block holders, Energy Beam Sciences, Agawam, MA) can be stained with water-soluble reagents and can be cut at 2 µm (Beckstead et al. 1981 ). These relatively thin sections, compared to the usual 4–6-µm paraffin sections and 10-µm frozen sections, provide excellent preservation of morphology and a larger number of serial sections of very small lesions. For preservation of enzymes, all of the fixation and embedding steps are carried out at 4C, and acetone dehydration is preferred to dehydration with ethyl alcohol (Beckstead et al. 1981 ; Pretlow et al. 1987 , Pretlow et al. 1990 ; Barrow et al. 1990 ). Multiple enzyme histochemical techniques have identified putative premalignant lesions in glycol methacrylate-embedded specimens of liver (Pretlow et al. 1987 ). Similar approaches have been useful in the study of human colon tissue (Pretlow et al. 1991 ) and the colons of carcinogen-treated animals (Barrow et al. 1990 ; Pretlow et al. 1990 ).

For demonstration of hexosaminidase activity and immunohistochemical demonstration of the incorporation of 5-bromo-2'-deoxyuridine (BUdR) (Sigma; St Louis, MO) in serial sections, the initial fixation of colon tissue was reduced to 15 min in 2% paraformaldehyde at 4C, followed by a 1-hr wash in 3% sucrose in 0.1 M phosphate buffer (pH 7.4), and fixation in 100% acetone for 2 hr under vacuum (Pretlow et al. 1994b ). More recently, the glycol methacrylate-embedding procedures were adapted for use with sections of whole human prostates for demonstration of altered enzyme activity with different pathological conditions (Monger et al. 1994 ).

Immunohistochemistry with Paraffin-embedded Tissue
Many antigens can now be demonstrated in formalin-fixed, paraffin-embedded tissues with antigen retrieval methods (Gown et al. 1993 ; Shi et al. 1991 , Shi et al. 1997 ). Mouse monoclonal antibodies to demonstrate the following antigens were obtained from the following suppliers: carcinoembryonic antigen (clone COL-1; Zymed, San Francisco, CA), nm23 (NCL-nm23; Vector Laboratories, Burlingame, CA), and BUdR (Chemicon; Temecula, CA). Biotinylated horse anti-mouse IgG was obtained from Vector; streptavidin–biotinylated horseradish peroxidase complex from Amersham (Arlington Heights, IL); Superfrost-Plus-treated slides from Fisher Scientific.


  Results and Discussion
Top
Summary
Introduction
Materials and Methods
Results and Discussion
Literature Cited

Enzyme-altered Foci in Liver Carcinogenesis
From the earliest studies of the induction of tumors in experimental animals, it was known that there is a long latency period between the first application of carcinogen and the final appearance of tumor(s) (reviewed in Pitot 1981 ). By the mid 1960s it was recognized that histological sections of grossly normal appearing liver from an animal treated with a carcinogen just a few weeks earlier contained discrete areas or "islands" of aberrant enzyme activity that are generally referred to as enzyme-altered foci (reviewed in Pitot 1981 ; Peraino et al. 1983 ). Serial sections of liver demonstrated that many foci displayed multiple phenotypic alterations, such as an increase in {gamma}-glutamyl transpeptidase activity and a decrease in bile canalicular ATPase activity (Pitot 1981 ; Peraino et al. 1983 ; Pretlow et al. 1987 ). Some of these phenotypic changes, such as increased glucose-6-phosphate dehydrogenase, the rate-limiting step in the pentose phosphate pathway (Weber 1977 ), reflect alterations that directly affect the increased rates of growth that occur during progression of the neoplastic process. Other alterations are not as well understood. These enzyme-altered foci in liver have been demonstrated to be monoclonal (Scherer and Hoffmann 1971 ; Rabes 1983 ) and are believed to be the earliest identifiable progeny of initiated cells. Hundreds of studies over the past 30 years have supported the hypothesis that these focal populations of enzyme-altered cells are putative premalignant lesions, i.e., at least some of these foci have the potential to progress to hepatocellular carcinomas (Peraino et al. 1983 ). Therefore, enzyme histochemistry has provided a tool with which to identify and follow the biochemical and molecular events that take place between initiation or the first application of carcinogen and the appearance of tumors in liver.

Enzyme-altered Foci in Colon Carcinogenesis
Knowing that enzyme-altered foci in liver had provided a tool that led to an increased understanding of liver carcinogenesis, we asked whether similar enzyme changes preceded morphological changes in the colon. For these studies we used serial sections of glycol methacrylate-embedded, grossly normal colons from F344 rats that had been treated with the colon carcinogen dimethylhydrazine (Barrow et al. 1988 , Barrow et al. 1990 ). Multiple lesions with altered enzyme activities were identified in the distal colon and rectum of these carcinogen-treated rats (Barrow et al. 1990 ). Decreased expression of hexosaminidase activity (Figure 1D) identified the largest proportion (71–76%) of these lesions, which varied morphologically from normal to overtly dysplastic and in size from a single crypt to five or more crypts (Barrow et al. 1990 ). Like liver foci, these colon enzyme-altered foci frequently displayed multiple phenotypic abnormalities, including decreased {alpha}-naphthyl butyrate esterase activity (Figure 1E) and a reduction in goblet cells (Figure 1F). A decrease in hexosaminidase activity was also seen in colon tumors (Pretlow et al. 1992a ; Pretlow and Pretlow 1997 ) that developed in these same animals. Hexosaminidase provides a marker with which to follow initiated colon epithelial cells throughout the carcinogenic process.

Aberrant Crypt Foci in Animals
While we were working on enzyme-altered foci in colons, Bird 1987 published the first description of ACF in whole-mounts of colons from carcinogen-treated rodents that had been stained with methylene blue and viewed at low power with a microscope. ACF are composed of one or more crypts that appear as a single focus and differ from other crypts in that they are larger, have a thickened layer of epithelial cells that stain darker, have an increased pericryptal area between them and the normal crypts, frequently have slit-shaped lumina, and are microscopically elevated above the adjacent normal crypts (Figure 1A–C). The first question we asked is, are ACF enzyme-altered? To address this question, we marked ACF, identified in methylene blue-stained colons from azoxymethane-treated F344 rats, with permanent ink and embedded the tissue in glycol methacrylate (Pretlow et al. 1990 ). All of the first 30 ACF identified in this way had decreased hexosaminidase activity (Pretlow et al. 1990 ). Subsequent studies with hundreds of ACF in F344 rats have found greater than 99% of ACF with decreased hexosaminidase activity. Many of the ACF display additional phenotypic alterations, such as decreased {alpha}-naphthyl butyrate esterase activity or increased periodic acid–Schiff-reactive material (Pretlow et al. 1992a ; Pretlow and Pretlow 1997 ), but the expression of these phenotypes is not altered uniformly in all ACF.

Having established that ACF are enzyme-altered, we wondered if all enzyme-altered foci in colons are ACF or if some enzyme-altered foci are morphologically normal. Our earlier studies with enzyme-altered foci in glycol methacrylate sections had suggested that some enzyme-altered foci were not larger than their adjacent normal crypts, but this was difficult to confirm because of the artifacts inherent in embedded tissue. By incubating fixed, intact, whole-mount colons from carcinogen-treated rats in the same substrate as was used for the histochemical demonstration of hexosaminidase activity in slides, we (Pretlow et al. 1993b ) were able to demonstrate two populations of lesions with decreased hexosaminidase activity: one with aberrant morphology that resembles ACF (Figure 1G) and the other with normal morphology (Figure 1H). Although both lesions appear to be induced by carcinogen, the relationship between them is not known.

Multiple studies of ACF in animals (reviewed in Pretlow et al. 1992a ; Pretlow 1994 ; Bird 1995 ; Pretlow and Pretlow 1997 ) support the hypothesis that ACF are putative premalignant lesions, some of which are capable of progressing to cancer. ACF are specifically induced by colon carcinogens (McLellan and Bird 1988 ), the number of crypts per focus increases with time after treatment with carcinogen (McLellan et al. 1991a ), and the proliferative activity in ACF is increased (McLellan et al. 1991b ; Pretlow 1994 ) and resembles that seen in colon tumors (Pretlow et al. 1994b ). The finding of invasive cancer in a lesion identified in a methylene blue-stained preparation of colon as an ACF (Pretlow 1994 ; Pretlow et al. 1992a ; Pretlow and Pretlow 1997 ) is further evidence for the role of ACF in colon tumorigenesis. Because ACF are observed as early as 2 weeks after a single dose of carcinogen and the entire colon can be scanned for these lesions in 1–2 hr, ACF have been used widely as intermediate biomarkers to assess the ability of agents to protect against or promote colon cancer (Pretlow et al. 1992b ; Magnuson et al. 1993 ; Pereira et al. 1994 ; Wargovich et al. 1995 , Wargovich et al. 1996 ); reviewed in Bird 1995 , Pretlow 1994 , Pretlow et al. 1992a . Molecular analysis of these microscopic lesions from animals (Stopera et al. 1992 ; Shivapurkar et al. 1994 ; Singh et al. 1994 ; Zaidi et al. 1995 ) has allowed the molecular characterization of some of the early events of colon carcinogenesis.

Aberrant Crypt Foci in Humans
Our laboratory was the first to report ACF in whole-mount preparations of grossly normal human colon mucosa (O'Riordan et al. 1990 ; Pretlow et al. 1991 ). The ACF in humans (Figure 1E and Figure 1F) clearly resemble those seen in animals in morphology and histological appearance (Pretlow et al. 1991 , Pretlow et al. 1994c ; Roncucci et al. 1991a , Roncucci et al. 1991b ; Pretlow 1994 ; Konstantakos et al. 1996 ; Siu et al. 1997 ). Although ACF from humans are enzyme-altered (O'Riordan et al. 1990 ; Pretlow et al. 1991 ), the enzyme alterations studied to date are not as marked or consistent as those observed in F344 rats. The finding that 93% of human ACF exhibit increased expression of carcinoembryonic antigen (Pretlow et al. 1994c ) provides an important corroborative marker for ACF in histological sections and possible insights regarding the role of this molecule in colon tumorigenesis (Augenlicht 1994 ). Siu et al. 1997 identified ACF in whole-mount human colons, embedded ACF in paraffin, and used the increased expression of carcinoembryonic antigen to identify these human ACF in histological sections for their evaluation of dysplasia. These ACF were sectioned longitudinally to permit visualization of the entire lengths of crypts. It was found that 54% of 50 ACF from 28 patients displayed dysplasia when serial sections of ACF were evaluated (Siu et al. 1997 ). This is a much higher proportion of human ACF with dysplasia than reported previously in patients with sporadic colon cancer for which only single sections were evaluated (Jen et al. 1994 ; Yamashita et al. 1995 ). Molecular analyses of human ACF have identified multiple genetic alterations in these microscopic lesions, including frequent mutations of K-ras (Pretlow et al. 1993a ; Jen et al. 1994 ; Smith et al. 1994 ; Yamashita et al. 1995 ), less frequent mutations of the APC gene (Jen et al. 1994 ; Smith et al. 1994 ), and genomic instability (Augenlicht et al. 1996 ; Heinen et al. 1996 ). It is hoped that continued studies of human ACF will provide further insights into the earliest genetic alterations that initiate and promote the development of this very common human cancer.

Enzyme-altered or Antigen-altered Foci in Human Prostate
The studies of putative premalignant lesions in human prostate in our laboratory are much more preliminary. Monger et al. 1994 , using sections of whole prostate embedded in glycol methacrylate, was the first to demonstrate focal areas of benign prostatic epithelium with a marked decrease of acid phosphatase and 5'-nucleotidase activities. It is interesting that prostate intraepithelial neoplasia (PIN), a putative precursor of invasive prostate cancer, similarly expresses decreased acid phosphatase and 5'-nucleotidase activities compared with both prostate cancer and benign prostate (Monger et al. 1994 ). Aberrant expression of CD44, transforming growth factor-{alpha}, and nm23 (Figure 2A and Figure 2B) also has been observed in a small number of benign prostate epithelial glands (Pretlow et al. 1994a , Pretlow et al. 1995 ) after staining of paraffin-embedded prostate tissues with monoclonal antibodies specific for these antigens. The increased expression of nm23 in the epithelium of some benign prostate glands (Figure 2A and Figure 2B) parallels the increased expression of this antigen in PIN (Figure 2C and Figure 2D) (Pretlow et al. 1995 ). Perhaps in the future these putative premalignant lesions will be used as biomarkers to evaluate chemopreventive agents for human prostate cancer.



View larger version (139K):
[in this window]
[in a new window]
 
Figure 2. Sections of human prostate. Immunohistochemical demonstration of increased expression of nm23 antigen in the epithelium of some benign prostate glands (A), adjacent section stained with H&E (B; from Pretlow et al. 1995 , with permission) and in prostate intraepithelial neoplasia (PIN) (arrows) and carcinoma (C), adjacent section stained with H&E (D). Bar = 60 µm.

In conclusion, histochemistry, including enzyme histochemistry of glycol methacrylate-embedded tissues, enzyme histochemistry of segments of intact tissue, and immunohistochemistry, has provided invaluable tools to identify and study putative premalignant lesions from their earliest identification through their progression to cancer.


  Acknowledgments

Supported in part by NIH grants CA66725, CA48032, CA54031, CA57179, DK45770, DK51347, and CA43703.

We thank the many students, research associates, and research assistants who contributed to this work, including Betty Barrow, Christopher Cheyer, Leon Hudson, Lawrence Monger, M. Nagabhushan, Mary Ann O'Riordan, and I-Mei Siu.

Received for publication August 7, 1997; accepted August 7, 1997.


  Literature Cited
Top
Summary
Introduction
Materials and Methods
Results and Discussion
Literature Cited

Augenlicht L (1994) Adhesion molecules, cellular differentiation, and colonic crypt architecture. Gastroenterology 107:1894-1898[Medline]

Augenlicht LH, Richards C, Corner G, Pretlow TP (1996) Evidence for genomic instability in human colonic aberrant crypt foci. Oncogene 12:1767-1772[Medline]

Bannasch P, Gössner W (1994) Pathology of Neoplasia and Preneoplasia in Rodents. EULEP Color Atlas of Pathology. Vol 1. New York, FK Schattauer

Bannasch P, Gössner W (1997) Pathology of Neoplasia and Preneoplasia in Rodents. EULEP Color Atlas of Pathology. Vol 2. New York, FK Schattauer

Barrow BJ, O'Riordan MA, Stellato TA, Calkins BM, Pretlow TP (1990) Enzyme-altered foci in colons of carcinogen-treated rats. Cancer Res 50:1911-1916[Abstract]

Barrow BJ, Ortiz–Reyes R, O'Riordan MA, Stellato TA, Pretlow TP (1988) Putative preneoplastic foci in colons of dimethylhydrazine-treated rats. FASEB J 2:A1154

Beckstead JH, Halverson PS, Ries CA, Bainton DF (1981) Enzyme histochemistry and immunohistochemistry on biopsy specimens of pathologic human bone marrow. Blood 57:1088-1098[Abstract]

Bird RP (1987) Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 37:147-151[Medline]

Bird RP (1995) Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 93:55-71[Medline]

Caderni G, Giannini A, Lancioni L, Luceri C, Biggeri A, Dolara P (1995) Characterisation of aberrant crypt foci in carcinogen-treated rats: association with intestinal carcinogenesis. Br J Cancer 71:763-769[Medline]

Gown AM, de Wever N, Battifora H (1993) Microwave-based antigenic unmasking. A revolutionary new technique for routine immunohistochemistry. Appl Immunohistochem 1:256-266

Heinen CD, Shivapurkar N, Tang Z, Groden J, Alabaster O (1996) Microsatellite instability in aberrant crypt foci from human colons. Cancer Res 56:5339-5341[Abstract]

Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B, Kinzler KW (1994) Molecular determinants of dysplasia in colorectal lesions. Cancer Res 54:5523-5526[Abstract]

Konstantakos AK, Siu I-M, Pretlow TG, Stellato TA, Pretlow TP (1996) Human aberrant crypt foci with carcinoma in situ from a patient with sporadic colon cancer. Gastroenterology 111:772-777[Medline]

Magnuson BA, Carr I, Bird RP (1993) Ability of aberrant crypt foci characteristics to predict colonic tumor incidence in rats fed cholic acid. Cancer Res 53:4499-4504[Abstract]

McLellan EA, Bird RP (1988) Specificity study to evaluate induction of aberrant crypts in murine colons. Cancer Res 48:6183-6186[Abstract]

McLellan EA, Medline A, Bird RP (1991a) Sequential analyses of the growth and morphological characteristics of aberrant crypt foci: Putative preneoplastic lesions. Cancer Res 51:5270-5274[Abstract]

McLellan EA, Medline A, Bird RP (1991b) Dose response and proliferative characteristics of aberrant crypt foci: putative preneoplastic lesions in rat colon. Carcinogenesis 12:2093-2098[Abstract]

Monger LE, Jr., Nagabhushan M, Pretlow TG, Pretlow TP (1994) A novel approach to the characterization of whole prostate pathology in glycol methacrylate. Am J Pathol 145:54-60[Abstract]

O'Riordan MA, Barrow BJ, Jurcisek JA, Stellato TA, Pretlow TP (1990) Aberrant crypts in the colons of humans and carcinogen-treated rats are enzyme-altered. Proc Am Assoc Cancer Res 31:85

Peraino C, Richards WL, Stevens FJ (1983) Multistage hepatocarcinogenesis. In Slaga TJ, ed. Mechanisms of Tumor Promotion. Vol 1. Boca Raton, FL, CRC Press, 1-53

Pereira MA, Barnes LH, Rassman VL, Kelloff GV, Steele VE (1994) Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 15:1049-1054[Abstract]

Pitot HC (1981) Fundamentals of Oncology. 2nd Ed. New York, Dekker

Pretlow TG, Nagabhushan M, Pretlow TP (1995) Prostatic intraepithelial neoplasia and other changes during promotion and progression. Pathol Res Pract 191:842-849[Medline]

Pretlow TG, Nagabhushan M, Sy M, Guo Y, Pretlow TP (1994a) Putative preneoplastic foci in the human prostate. J Cell Biochem Suppl 19:224-231[Medline]

Pretlow TP (1994) Alterations associated with early neoplasia in the colon. In Pretlow TG, Pretlow TP, eds. Biochemical and Molecular Aspects of Selected Cancers. Vol 2. San Diego, Academic Press, 93-141

Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA, Stellato TA (1991) Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 51:1564-1567[Abstract]

Pretlow TP, Brasitus TA, Fulton NC, Cheyer C, Kaplan EL (1993a) K-ras mutations in putative preneoplastic lesions in human colon. J Natl Cancer Inst 85:2004-2007[Abstract]

Pretlow TP, Cheyer C, O'Riordan MA (1994b) Aberrant crypt foci and colon tumors in F344 rats have similar increases in proliferative activity. Int J Cancer 56:599-602[Medline]

Pretlow TP, Grane RW, Goehring PL, Lapinsky AS, Pretlow TG (1987) Examination of enzyme-altered foci with gamma-glutamyl transpeptidase, aldehyde dehydrogenase, glucose-6-phosphate dehydrogenase, and other markers in methacrylate-embedded liver. Lab Invest 56:96-100[Medline]

Pretlow TP, O'Riordan MA, Kolman MF, Jurcisek JA (1990) Colonic aberrant crypts in azoxymethane-treated F344 rats have decreased hexosaminidase activity. Am J Pathol 136:13-16[Abstract]

Pretlow TP, O'Riordan MA, Pretlow TG, Stellato TA (1992a) Aberrant crypts in human colonic mucosa: putative preneoplastic lesions. J Cell Biochem Suppl 16G:55-62

Pretlow TP, O'Riordan MA, Somich GA, Amini SB, Pretlow TG (1992b) Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis 13:1509-1512[Abstract]

Pretlow TP, O'Riordan MA, Spancake KM, Pretlow TG (1993b) Two types of putative preneoplastic lesions identified by hexosaminidase activity in whole-mounts of colons from F344 rats treated with carcinogen. Am J Pathol 142:1695-1700[Abstract]

Pretlow TP, Pretlow TG (1997) Neoplasia and preneoplasia of the intestines. In Bannasch P, Gössner W, eds. Pathology of Neoplasia and Preneoplasia in Rodents. EULEP Color Atlas of Pathology. Vol 2. New York, FK Schattauer, 75-94

Pretlow TP, Roukhadze E, O'Riordan MA, Chan JC, Amini SB, Stellato TA (1994c) Carcinoembryonic antigen in human colonic aberrant crypt foci. Gastroenterology 107:1719-1725[Medline]

Rabes HM (1983) Development and growth of early preneoplastic lesions induced in the liver by chemical carcinogens. J Cancer Res Clin Oncol 106:85-92[Medline]

Roncucci L, Medline A, Bruce WR (1991a) Classification of aberrant crypt foci and microadenomas in human colon. Cancer Epidemiol Biomarkers Prev 1:57-60[Abstract]

Roncucci L, Stamp D, Medline A, Cullen JB, Bruce WR (1991b) Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 22:287-294[Medline]

Scherer E, Hoffmann M (1971) Probable clonal genesis of cellular islands induced in rat liver by diethylnitrosamine [Letter]. Eur J Cancer 7:369-371[Medline]

Shi S-R, Cote RJ, Taylor CR (1997) Antigen retrieval immunohistochemistry: past, present, and future. J Histochem Cytochem 45:327-343[Abstract/Free Full Text]

Shi SR, Key ME, Kalra KL (1991) Antigen retrieval in fromalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741-748[Abstract]

Shivapurkar N, Tang Z, Ferreira A, Nasim S, Garett C, Alabaster O (1994) Sequential analysis of K-ras mutations in aberrant crypt foci and colonic tumors induced by azoxymethane in Fischer-344 rats on high-risk diet. Carcinogenesis 15:775-778[Abstract]

Singh J, Kulkarni N, Kelloff G, Reddy BS (1994) Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis. Carcinogenesis 15:1317-1323[Abstract]

Siu I-M, Pretlow TG, Amini SB, Pretlow TP (1997) Identification of dysplasia in human colonic aberrant crypt foci. Am J Pathol 150:1805-1813[Abstract]

Smith AJ, Stern HS, Penner M, Hay K, Mitri A, Bapat BV, Gallinger S (1994) Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 54:5527-5530[Abstract]

Stopera SA, Murphy LC, Bird RP (1992) Evidence for a ras gene mutation in azoxymethane-induced colonic aberrant crypts in Sprague-Dawley rats: earliest recognizable precursor lesions of experimental colon cancer. Carcinogenesis 13:2081-2085[Abstract]

Wargovich MJ, Chen CD, Harris C, Yang E, Velasco M (1995) Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int J Cancer 60:515-519[Medline]

Wargovich MJ, Chen C-D, Jimenez A, Steele VE, Velasco M, Stephens LC, Price R, Gray K, Kelloff GJ (1996) Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol Biomarkers Prev 5:355-360[Abstract]

Weber G (1977) Enzymology of cancer cells. N Engl J Med 296:486–493, 541–551

Yamashita N, Minamoto T, Ochia A, Onda M, Esumi H (1995) Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of colon. Gastroenterology 108:434-440[Medline]

Zaidi NH, Pretlow TP, O'Riordan MA, Dumenco LL, Allay E, Gerson SL (1995) Transgenic expression of human MGMT protects against azoxymethane induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. Carcinogenesis 16:451-456[Abstract]